For seven years, the Institute of Human Virology has provided a forum for dedicated scientists in the fields of virology, most specifically HIV/AIDS and cancer biology, to present new data and exchange ideas and views. The Annual Meeting serves as a unique conference with the following aims: ? 1. To disseminate the most current research findings within the selected program topics; ? 2. To critically assess the impact of new findings on future directions for research; ? 3. To provide a forum for discussion of current and emerging issues; ? 4. To identify, support, and build the next generation of AIDS researchers; ? 5. To increase participation by women, ethnic/racial minorities, and other individuals who have been traditionally underrepresented in science, yet overrepresented in the populations impacted most by the disease, and to increase participation by individuals from the developing world. ? ? The Institute of Human Virology (IHV), with the financial support requested in this application, will accomplish these aims: a) by attracting world-renown senior scientists as presenters and participants; b) by carefully organizing each dedicated conference session with theoretically divergent perspectives and ethnically diverse participants; c) by enriching the scientific sessions with an open schedule to foster dialog and interaction between and among investigators; d) by reaching out to and promoting the participation of young investigators in poster sessions and scholarship initiatives; and e) by ensuring that conference results are shared with the broader scientific community through publication of all speaker and poster abstracts. The Annual Meeting is strengthened by a strictly enforced press policy, one that protects data presented at the Annual Meeting for future peer-reviewed publication. This policy prohibits the members of the press from disclosing any information presented at the Annual Meeting without the permission of the presenter. An estimated 900 scientists and clinicians from around the world are expected to participate in this five-day meeting scheduled for September 29-October 3, 2003 at the Baltimore Marriott Waterfront Hotel. ? ? The Annual Meeting features a single-track format. Each conference session opens with a senior scientist's overview presentation on the current base of knowledge in the topic of discussion. This overview provides a basis for evaluation of the data presented by a panel of speakers, each sharing the results of their work. The Annual Meeting Program Committee, responsible for the program content, is encouraged to invite speakers with differing perspectives to stimulate open discussion. Posters are displayed throughout the meeting. One evening is set aside for a reception in the poster area to encourage attendance and interaction. Evening social events are provided to encourage participants to meet with current and potential collaborators, and to talk with presenters. The Annual Meeting Scholarship Initiative provides funds to ensure the participation of promising women, ethnic and racial minorities, and other individuals who have been traditionally underrepresented in science, as well as participants from the developing world. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Conference (R13)
Project #
2R13AI046078-04
Application #
6720130
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Program Officer
Baron, Patricia A
Project Start
1999-08-18
Project End
2004-08-31
Budget Start
2003-09-15
Budget End
2004-08-31
Support Year
4
Fiscal Year
2003
Total Cost
$38,500
Indirect Cost
Name
University of MD Biotechnology Institute
Department
Type
Organized Research Units
DUNS #
603819210
City
Baltimore
State
MD
Country
United States
Zip Code
21202
Mathias, C B; Schramm, C M; Guernsey, L A et al. (2017) IL-15-deficient mice develop enhanced allergic responses to airway allergen exposure. Clin Exp Allergy 47:639-655
Mathias, C B; Guernsey, L A; Zammit, D et al. (2014) Pro-inflammatory role of natural killer cells in the development of allergic airway disease. Clin Exp Allergy 44:589-601